Prendes Brandon L, Aubin-Pouliot Annick, Egbert Nitin, Ryan William R
Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco, San Francisco, California, USA
University of California-San Francisco, School of Medicine, San Francisco, California, USA.
Otolaryngol Head Neck Surg. 2014 Sep;151(3):462-7. doi: 10.1177/0194599814537444. Epub 2014 Jun 3.
This study aimed to assess the rate of occult metastases in patients with head and neck mucosal squamous cell carcinoma who have undergone therapeutic neck radiation, and then develop primary site recurrence, without clinical evidence of recurrent neck disease.
Case series with chart review.
Tertiary care center.
Head and neck mucosal squamous cell carcinoma patients with N+ necks treated with primary radiation who developed primary site recurrence with radiologically resolved neck lymphadenopathy, treated with salvage primary-site surgery with or without elective cervical lymphadenectomy (ECL). Main outcome measures were rate of occult nodal metastases, complication rates, and disease-free survival.
Sixteen patients met inclusion criteria. Of 18 neck sides that underwent either ECL or observation for a mean follow-up of 26 months, 4 (22.2%) were found to have positive occult cervical metastases, all on the ipsilateral side of preradiation neck disease. Patients with advanced T-stage and/or free flap reconstruction were more likely to undergo cervical lymphadenectomy. Patients with persistent (as opposed to recurrent) primary site tumors had the highest rate of occult cervical metastases.
The risk of occult nodal metastases of 22.2%, in this study, may be too high to justify routinely omitting elective cervical lymphadenectomy in this patient population. Lymphadenectomy should especially be considered in patients with persistent tumors, with advanced recurrent T-stage, and undergoing free flap reconstruction.
本研究旨在评估接受颈部治疗性放疗、随后出现原发部位复发且无颈部疾病复发临床证据的头颈部黏膜鳞状细胞癌患者的隐匿性转移率。
病例系列研究并进行病历回顾。
三级医疗中心。
头颈部黏膜鳞状细胞癌伴N+颈部的患者接受原发灶放疗,出现原发部位复发且颈部淋巴结病变经影像学检查已消退,接受挽救性原发部位手术,可选择或不选择选择性颈淋巴结清扫术(ECL)。主要观察指标为隐匿性淋巴结转移率、并发症发生率和无病生存率。
16例患者符合纳入标准。在18个接受ECL或观察的颈部侧别中,平均随访26个月,发现4例(22.2%)有隐匿性颈部转移阳性,均位于放疗前颈部疾病的同侧。T分期较晚和/或进行游离皮瓣重建的患者更有可能接受颈淋巴结清扫术。原发部位肿瘤持续存在(而非复发)的患者隐匿性颈部转移率最高。
本研究中隐匿性淋巴结转移风险为22.2%,可能过高,以至于在该患者群体中常规省略选择性颈淋巴结清扫术不合理。对于肿瘤持续存在、T分期较晚且进行游离皮瓣重建的患者,尤其应考虑进行淋巴结清扫术。